On May 22, local time, according to reports from local health officials, the US state of Michigan has confirmed the state's second case of human infection with bird flu. The infected person was a farm worker who had mild symptoms and quickly recovered after being infected. According to reports, this is the third case of bird flu reported across the US this year. Last month, a farm worker in the southern US state of Texas developed symptoms such as red eyes after being exposed to sick cows. This is the first case of bird flu in the US this year.

The US side confirmed the second case of human infection with bird flu on Wednesday. Affected by this, vaccine concept stocks rose across the board.

By the close, BioNTech was up 11.1%, CureVac was up 18.8%, Modena was up 13.7%, and Vir Biotechnology was up 11.4%. Pfizer, which announced a layoff plan earlier this month and is expected to face additional expenses of US$1.7 billion as a result, was also up 3.7%.

Market news: Moderna and Pfizer are discussing the H5N1 avian influenza vaccine with the US.

Kong Fanyi, head of the Department of Infectious Diseases and chair professor at the Department of Internal Medicine at the University of Hong Kong Medical School, said that Hong Kong is currently in the respiratory syncytial virus epidemic season. It is expected that cases will continue to rise. The peak infection period is generally from July to September. High-risk people over the age of 60 and diabetics are urged to get the RSV vaccine as soon as possible.

Vaccine-related companies include:

Shengnuo Pharmaceutical-B (02257), Clover Bio-B (02197), Cansino Biotech (06185), Emmy vaccine (06660), etc.